News

Researchers calculated that 262,591 people in the United States received an hypertrophic cardiomyopathy diagnosis in 2019, an increase of 60% from 164,403 calculated to have been diagnosed in 2013.

Identifying the right payer before a healthcare service is provided and billing on time, reduces costs, prevents bad debt and maximizes reimbursements and revenue.

In this week's episode, Senior Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with Chief Medical Officer of Caravan Health, Ashok Roy. The two dug into the approach of delivering quality care at Caravan, discussed ACOs in care and population health.

New infections are down and wider use of pre-exposure prophylaxis would decrease them further.

The adoption of healthcare IT leads as the main driver of growth.

Results from Year 6 of the Independence-at-Home demonstration project also did not show reductions in hospital admissions and emergency department visits.

The three guiding principles of digital tool design are plan around user experience; aim high with creative, strategic thinking; and ensure that digital transformation is supported with top-down commitment.

Merck now says molnupiravir reduces the risk of hospitalization or death from COVID-19 by 30% after all data have been analyzed. Previously, an interim analysis showed a 50% reduction in hospitalization or death.

A roundup of the latest news about the omicron coronavirus.

A round-up of news about the new variant of the coronavirus.

The No Surprises Act is scheduled to go into effect in January. The law will require providers to provide patients with details of the new balance billing requirements, any state-level limitations or prohibitions in the state of service, and the dispute resolution process.

New research confirms that regardless of age or severity of COVID-19 infection, prolonged effects on cognitive function are possible.

The $56,000 price tag is a rational response to an irrational insurance system, says a Berkeley Public Health economist in an opinion piece in this week’s New England Journal of Medicine.

Briana Contreras, associate editor of Managed Healthcare Executive spoke with WellRight CEO, Neepa Patel, on the topic of wellness programs in healthcare and the need for employers and health plans to roll out new, effective, holistic and innovative programs for patients. Patel did discuss the challenges that some organization can face when rolling out these programs, but she explained how accessible, affordable and beneficial these programs are for patients mental health and wellbeing.

When women are underrepresented in healthcare — half of our world’s population becomes at-risk.

The traditional dividing line between transmission by droplets and smaller aerosols is incorrect, say the authors of a Annals of Internal Medicine review paper, and infection control measures need to reflect the new understanding that respiratory viruses spread in respiratory particles of all sizes and perhaps mainly in aerosols.

The incidence of brain swelling was highest in the group of patients who received the highest doses of Aduhelm, as well as the group of patients who are carriers of the APoE gene.

The shift to value-based care in the U.S. has been slow in coming, in large part because providers have continued to cling to the traditional “fee for service” healthcare model that historically has worked well for them.

Several new generics have launched in the United States, including for the migraine therapy Zomig, the anticancer therapy Doxil, and an anti-inflammatory used to treat respiratory conditions associated with COVID-19.

Two key health provisions in the House “BBB “ would empower CMS to negotiate the prices of 10 drugs starting in 2023 and put a limit of $2,000 on Medicare Part D annual out-of-pocket costs.

U.S. workers plan to spend more time reviewing their healthcare options and enrolling in new benefits during this enrollment period

Pfizer/BioNTech plan to use this data to support submissions for full approval of the vaccine in those 12 to 15 years old.

Momentum is building for biosimialrs but robust coverage for lower-cost agents, including biosimilars, is needed.

As industries across the board move towards a digital-only world, pharma companies must account for the different technologies that are transforming the R&D process.

In COVID-19 news, FDA expands EUA for Moderna/Pfizer boosters and Pfizer seeks EUA for oral antiviral. Keytruda receives another indication, first therapy is approved for dwarfism, FDA extends review of mavacamten, and Gilead submits application for chronic hepatitis therapy.

The decision on the fate of the novel therapy for hypertrophic cardiomyopathy was delayed because the agency said it needed more time to consider the risk evaluation and mitigation strategy (REMS) for the drug.

Using predictive analytics to address social determinants of Health and transportation barriers.